AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), and AbbVie announced that The Phase III VERONA study, which evaluated Venclexta or venetoclax in combination with azacitidine for ...

This week, a FDA approval of AbbVie's Venclexta in some patients with relapsing chronic lymphocytic leukemia puts the company a step closer to its goal, but a drug on the horizon with ties to ...

The VERONA study tested the combination of Venclexta and azacitidine against azacitidine plus placebo. Results showed a hazard ratio (HR) of 0.908, indicating that AbbVie’s combination therapy ...